{"disease":{"id":"paroxysmal-nocturnal-hemoglobinuria","name":"Paroxysmal nocturnal hemoglobinuria","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":10},"drugs":{"marketed":[{"drug_id":"ravulizumab","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultomiris","generic_name":"RAVULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitor [EPC]","quality_score":75,"revenue":"5100","mechanism":"Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells."},{"drug_id":"crovalimab","indication_name":"paroxysmal nocturnal hemoglobinuria (PNH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piasky","generic_name":"CROVALIMAB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Complement C5 Inhibitor [EPC]","quality_score":62,"revenue":null,"mechanism":"Piasky works by blocking the action of the Complement C5 protein, which is involved in the immune system's response to foreign substances."},{"drug_id":"eculizumab","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"H5G1.1","generic_name":"ECULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":56,"revenue":null,"mechanism":"Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation."},{"drug_id":"iptacopan","indication_name":"Paroxysmal Nocturnal Hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fabhalta","generic_name":"IPTACOPAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Factor B","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Iptacopan binds to Factor B, regulating C3 cleavage and downstream effects in the alternative complement pathway, controlling IVH and EVH in PNH and inhibiting local activation in IgAN and C3G."},{"drug_id":"ravulizumab-cwvz","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ULTOMIRIS","generic_name":"RAVULIZUMAB-CWVZ","company_name":"ALEXION PHARM","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ultomiris","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ultomiris","company_name":"Alexion Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"eculizumab-aeeb","indication_name":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BKEMV","generic_name":"ECULIZUMAB-AEEB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Complement Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"soliris","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Soliris","company_name":"Apellis Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01374360","title":"Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry","phase":"","overall_status":"COMPLETED","enrollment_count":6061,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06524726","title":"The International PNH Interest Group PNH Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"International PNH Interest Group","has_results":false},{"nct_id":"NCT06154512","title":"A Real-world, Multi-center, Prospective, Observational Study for PNH in China","phase":"","overall_status":"COMPLETED","enrollment_count":724,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05755867","title":"Global PNH Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Aplastic Anemia and MDS International Foundation","has_results":false},{"nct_id":"NCT02946463","title":"ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04434092","title":"A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":210,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04747613","title":"Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":208,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03056040","title":"ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05744921","title":"A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":202,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03329365","title":"Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT05776472","title":"A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT04432584","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":190,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05133531","title":"A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":190,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04330534","title":"First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":false},{"nct_id":"NCT03748823","title":"Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":139,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06411626","title":"Home Reported Outcomes in PNH","phase":"","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06933914","title":"Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Wuhan Createrna Science and Technology Co., Ltd","has_results":false},{"nct_id":"NCT05274633","title":"Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria","phase":"","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06606314","title":"Specified Drug-use Surveillance of Fabhalta Capsules","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04558918","title":"Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05842486","title":"Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients","phase":"","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04469465","title":"Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03500549","title":"Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05389449","title":"A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05490017","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Kira Pharmacenticals (US), LLC.","has_results":false},{"nct_id":"NCT06931691","title":"A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06593938","title":"A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Chengdu Suncadia Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06312644","title":"Study of Ultomiris® (Ravulizumab) Safety in Pregnancy","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06294301","title":"A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Longbio Pharma","has_results":false},{"nct_id":"NCT05125341","title":"Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"CARE Pharma Shanghai Ltd.","has_results":false},{"nct_id":"NCT05642585","title":"A Study of Single-dose MY008211A in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Wuhan Createrna Science and Technology Co., Ltd","has_results":false},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT06412497","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03520647","title":"Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT06326814","title":"A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04085601","title":"A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05630001","title":"Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04654468","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04058158","title":"A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Samsung Bioepis Co., Ltd.","has_results":true},{"nct_id":"NCT07413250","title":"Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07229235","title":"REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07413679","title":"Long-term Safety of Danicopan: IPIG Registry-based Cohort Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07470762","title":"Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05876312","title":"Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"ADARx Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04679103","title":"A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC \"GENERIUM\", Russian Federation)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"AO GENERIUM","has_results":false},{"nct_id":"NCT06561841","title":"A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT04671810","title":"Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®","phase":"","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"AO GENERIUM","has_results":false},{"nct_id":"NCT03818607","title":"A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Amgen","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}